Diablo Clinical Research features a state-of-the-art Phase I Unit recently expanded

Diablo Clinical Research is proud to announce the completion of our Phase I unit expansion. Our new 2700 sq. ft. unit has five beds, three additional chairs for pharmacokinetic studies and three exam rooms. In addition, for our patient's comfort during their extended stays, our expanded unit has a shower, kitchen, internet access and a lounge area with a flat screen television.

These early phase/phase I clinical research studies are looking at short-term treatments to preserve beta cell function in type 1 diabetes, nerve regeneration in diabetic neuropathy patients, inhaled insulin for both Type 1 and Type 2 diabetics, Continuous Glucose Monitoring for both Type 1 and Type 2 diabetics, and many other studies related to diabetes, cholesterol, weight loss and more.

Study related medication, exams and devices are provided at no cost. Qualified study participants will also receive compensation for their time and travel. For further information please contact John McAdams in our Phase I unit at (925) 930-7267, extension 213.